Current therapeutic approach to mixed vulvovaginal infections
DOI: 10.32364/2618-8430-2021-4-2-144-148
T.V. Tazina
Ryazan State Medical University, Ryazan, Russian Federation
The evolutionarily formed community of symbiotic microbes harbored by a healthy vagina (or vaginal microbiota) contains not only Lactobacillus spp. but also many opportunistic microbes. These microbes can become pathogenic under the effects of exogenous factors and provoke vulvovaginitis whose symptoms force to see a gynecologist. Therefore, treatment of mixed vulvovaginal infections is still an important issue. Both the polymicrobial nature of these inflammatory diseases and increasing antimicrobial resistance should be considered when prescribing medications. This paper reviews current therapeutic approaches to mixed vulvovaginal infections and, in particular, emphasizes the most common causative agents. The mechanism and type of action of active ingredients of complex vaginal preparations to prevent polypharmacy and provide an etiological, topical, effective, and safe treatment are described in detail. The authors emphasize that therapeutic efficacy and safety of any vaginal formulations depend on both the content of active ingredients and the rate and completeness of their release, submucosal and systemic absorption.
Keywords: co-infection, bacterial vaginosis, vulvovaginal candidosis, metronidazole, miconazole, drug formulations.
For citation: Tazina T.V. Current therapeutic approach to mixed vulvovaginal infections. Russian Journal of Woman and Child Health. 2021;4(2):144–148. DOI: 10.32364/2618-8430-2021-4-2-144-148.
Acknowledgment
Editorial Board is grateful to LLC "Innolek" for the assistance in technical edition of this publication.
About the author:
Tatyana V. Tazina — Cand. of Sci. (Med.), Associate Professor, Department of Surgery, Obstetrics, & Gynecology of the Faculty of Postgraduate Education, Ryazan State Medical University; 9, Vysokovol’tnaya str., Ryazan, 390026, Russian Federation; ORCID iD 0000-0003-1029-0390.
Contact information: Tatyana V. Tazina, e-mail: tazina@inbox.ru. Financial Disclosure: the author has no a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 11.03.2021, revised 05.04.2021, accepted 28.04.2021.
2. Healthcare in Russia. 2019: Statistical Compendium/Rosstat. M.; 2019 (in Russ.).
3. Clinical guidelines for the diagnosis and treatment of diseases accompanied by pathological discharge from the genital tract of women. 2nd ed. M.: ROAG; 2019 (in Russ.).
4. Aleev I.A. The theory of fuzzy sets. The Vaginal infection combination puzzle: a new look. StatusPraesens. Gynecology, obstetrics, sterile marriage. 2015;2(25):42–49 (in Russ.).
5. Rivers C.A., Adaramola O.O., Schwebke J.R. Prevalence of bacterial vaginosis and vulvovaginal candidiasis mixed infection in a southeastern american STD clinic. Sex Transm Dis. 2011;38(7):672–674. DOI: 10.1097/OLQ.0b013e31820fc3b8.
6. Sobel J.D., Subramanian C., Foxman B. et al. Mixed vaginitis — more than coinfection and with therapeutic implications. Curr Infect Dis Rep. 2013;15(2):104–108. DOI: 10.1007/s11908-013-0325-5.
7. Jahic M., Mulavdic M., Nurkic J. et al. Clinical characteristics of aerobic vaginitis and it’s association to vaginal candidiasis, Trichomonas vaginalis and bacterial vaginosis. Mad Arch. 2013;67(6):428–430. DOI: 10.5455/medarh.2013.67.428-430.
8. Mashkovskij M.D. Medicines. M.: New Wave; 2014 (in Russ.).
9. Roe F.J. Safety of nitroimidazoles. Scand J Infect Dis Suppl. 1985;46:72–81. PMID: 3865353.
10. Crozet M.D., Terme T., Vanelle P. Designing new 5-nitroimidazoles: towards safer anti-infectious agents. Letters in Drug Design and Discovery. 2014;11(5):531–559. DOI: 10.2174/1570180810666131122010615.
11. Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Metronidazole. [Updated 2020 Feb 20].
12. Alper M.M., Barwin B.N., McLean W.M. et al. Systemic absorption of metronidazole by the vaginal route. Obstet Gynecol. 1985;65(6):781–784. PMID: 4000568.
13. Gajdács M., Spengler G., Urbán E. Identification and antimicrobial susceptibility testing of anaerobic bacteria: rubik’s cube of clinical microbiology? Antibiotics (Basel). 2017;6(4):25. DOI: 10.3390/antibiotics6040025.
14. Radzinskij V.E., Ordijanc I.M. Two-step therapy for vaginal infections. M.: StatusPraesens; 2012 (in Russ.).
15. Beigi R.H., Austin M.N., Meyn L.A. et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynec. 2004;191:1124–1129. DOI: 10.1016/j.ajog.2004.05.033.
16. Petrina M.A.B., Cosentino L.A., Rabe L.K., Hillier S.L. Susceptibility of bacterial vaginosis (BV) — associated bacteria to secnidazole compared to metronidazole, tinidazole and clindamycin. Anaerobe. 2017;47:115–119. DOI: 10.1016/j.anaerobe.2017.05.005.
17. Smirnova T.A., Didenko L.V., Azizbekjan R.R., Romanova Ju.M. Structural and functional characteristics of bacterial biofilms. Microbiology. 2010;79(4):435–446 (in Russ.).
18. McMillan А., Dell M., Zellar M.P. et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces. 2011;86(1):58–64. DOI: 10.1016/j.colsurfb.2011.03.016.
19. Khryanin A.A., Reshetnikov O.V. Bacterial vaginosis. New concepts of microbial biological environment and treatment options. Medical Council. 2014;(17):128–133 (in Russ.). DOI: 10.21518/2079-701X-2014-17-128-133.
20. Kukes V.G., ed. Clinical pharmacokinetics: theoretical, applied and analytical aspects: manual. M.: GEOTAR-Media; 2009 (in Russ.).
21. Golovkin V.A., Golovkin V.V., Golovkin A.V. Vaginal Medicines: Features of Development, Research and Application. Zaporozhye: Vidavets; 2000 (in Russ.).
22. Ginocaps. Instructions for medical use - RU No. LP-004061 (Electronic resource.) URL: https://www.rlsnet.ru/tn_index_id_94522.htm (access date: 02.25.2021) (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать